These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 35973529)

  • 1. Burden of Glaucoma in the United Kingdom: A Multicenter Analysis of United Kingdom Glaucoma Services.
    Fu DJ; Ademisoye E; Shih V; McNaught AI; Khawaja AP
    Ophthalmol Glaucoma; 2023; 6(1):106-115. PubMed ID: 35973529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT.
    Gazzard G; Konstantakopoulou E; Garway-Heath D; Garg A; Vickerstaff V; Hunter R; Ambler G; Bunce C; Wormald R; Nathwani N; Barton K; Rubin G; Morris S; Buszewicz M
    Health Technol Assess; 2019 Jun; 23(31):1-102. PubMed ID: 31264958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma.
    Lee PP; Walt JG; Doyle JJ; Kotak SV; Evans SJ; Budenz DL; Chen PP; Coleman AL; Feldman RM; Jampel HD; Katz LJ; Mills RP; Myers JS; Noecker RJ; Piltz-Seymour JR; Ritch RR; Schacknow PN; Serle JB; Trick GL
    Arch Ophthalmol; 2006 Jan; 124(1):12-9. PubMed ID: 16401779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Outcomes of Selective Laser Trabeculoplasty in the United Kingdom.
    Khawaja AP; Campbell JH; Kirby N; Chandwani HS; Keyzor I; Parekh M; McNaught AI;
    Ophthalmology; 2020 Jun; 127(6):748-757. PubMed ID: 31952882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term medical management of primary open-angle glaucoma and ocular hypertension in the UK: optimizing cost-effectiveness and clinic resources by minimizing therapy switches.
    Orme M; Collins S; Loftus J
    J Glaucoma; 2012 Sep; 21(7):433-49. PubMed ID: 21677590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glaucoma referral refinement in Ireland: managing the sensitivity-specificity paradox in optometric practice.
    Barrett C; O'Brien C; Loughman J
    Ophthalmic Physiol Opt; 2018 Jul; 38(4):400-410. PubMed ID: 29492992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary trabeculectomy versus primary glaucoma eye drops for newly diagnosed advanced glaucoma: TAGS RCT.
    King AJ; Fernie G; Hudson J; Kernohan A; Azuara-Blanco A; Burr J; Homer T; Shabaninejad H; Sparrow JM; Garway-Heath D; Barton K; Norrie J; McDonald A; Vale L; MacLennan G
    Health Technol Assess; 2021 Nov; 25(72):1-158. PubMed ID: 34854808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression from ocular hypertension to visual field loss in the English hospital eye service.
    Kelly SR; Khawaja AP; Bryan SR; Azuara-Blanco A; Sparrow JM; Crabb DP
    Br J Ophthalmol; 2020 Oct; 104(10):1406-1411. PubMed ID: 32217541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tackling the NHS glaucoma clinic backlog issue.
    Broadway DC; Tibbenham K
    Eye (Lond); 2019 Nov; 33(11):1715-1721. PubMed ID: 31110230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining optical coherence tomography with visual field data to rapidly detect disease progression in glaucoma: a diagnostic accuracy study.
    Garway-Heath DF; Zhu H; Cheng Q; Morgan K; Frost C; Crabb DP; Ho TA; Agiomyrgiannakis Y
    Health Technol Assess; 2018 Jan; 22(4):1-106. PubMed ID: 29384083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resource use and costs of patients with glaucoma or ocular hypertension: a one-year study based on retrospective chart review in the Netherlands.
    Oostenbrink JB; Rutten-van Mölken MP; Sluyter-Opdenoordt TS
    J Glaucoma; 2001 Jun; 10(3):184-91. PubMed ID: 11442180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Health Of Patients' Eyes (HOPE) Glaucoma study. The effectiveness of a 'glaucoma personal record' for newly diagnosed glaucoma patients: study protocol for a randomised controlled trial.
    Forbes M; Fairlamb H; Jonker L
    Trials; 2015 Aug; 16():337. PubMed ID: 26248726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct costs of glaucoma management following initiation of medical therapy. A simulation model based on an observational study of glaucoma treatment in Germany.
    Kobelt G; Jönsson L; Gerdtham U; Krieglstein GK
    Graefes Arch Clin Exp Ophthalmol; 1998 Nov; 236(11):811-21. PubMed ID: 9825256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Portsmouth-based glaucoma refinement scheme: a role for virtual clinics in the future?
    Trikha S; Macgregor C; Jeffery M; Kirwan J
    Eye (Lond); 2012 Oct; 26(10):1288-94. PubMed ID: 22766539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring ocular hypertension, how much and how often? A cost-effectiveness perspective.
    Hernández R; Burr JM; Vale L; Azuara-Blanco A; Cook JA; Banister K; Tuulonen A; Ryan M;
    Br J Ophthalmol; 2016 Sep; 100(9):1263-8. PubMed ID: 26659710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct cost and predictive factors for treatment in patients with ocular hypertension or early, moderate and advanced primary open-angle glaucoma: the CoGIS study in Germany.
    Lorenz K; Wolfram C; Breitscheidel L; Shlaen M; Verboven Y; Pfeiffer N
    Graefes Arch Clin Exp Ophthalmol; 2013 Aug; 251(8):2019-28. PubMed ID: 23624617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for late presentation in chronic glaucoma.
    Fraser S; Bunce C; Wormald R
    Invest Ophthalmol Vis Sci; 1999 Sep; 40(10):2251-7. PubMed ID: 10476790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surveillance for ocular hypertension: an evidence synthesis and economic evaluation.
    Burr JM; Botello-Pinzon P; Takwoingi Y; Hernández R; Vazquez-Montes M; Elders A; Asaoka R; Banister K; van der Schoot J; Fraser C; King A; Lemij H; Sanders R; Vernon S; Tuulonen A; Kotecha A; Glasziou P; Garway-Heath D; Crabb D; Vale L; Azuara-Blanco A; Perera R; Ryan M; Deeks J; Cook J
    Health Technol Assess; 2012 Jun; 16(29):1-271, iii-iv. PubMed ID: 22687263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health care resources and costs for treating peripheral artery disease in a managed care population: results from analysis of administrative claims data.
    Margolis J; Barron JJ; Grochulski WD
    J Manag Care Pharm; 2005; 11(9):727-34. PubMed ID: 16300416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.